Titlebook: Experimental and Applied Immunotherapy; Jeffrey Medin,Daniel Fowler Book 2011 Springer Science+Business Media, LLC 2011 Cancer.Immunothera

不妥协

Tumor-Specific Mutations as Targets for Cancer Immunotherapyroteins. When pathogens enter a host, they introduce foreign proteins to which the host is not tolerant, and an immune response ensues. In contrast, tumors represent a special case, as the vast majority of tumor proteins are “self” and hence do not trigger immune activation. However, mutation of gen

CODA

Counteracting Subversion of MHC Class II Antigen Presentation by Tumorsmor growth is well established, we are still looking for ways to harness the MHC class II antigen presentation pathway for the development of an efficient immune response. Learning the mechanisms by which tumors circumvent the immune responses is the first step towards the development of cell-based

BATE

变色龙

T Regulatory Cells and Cancer Immunotherapyuncontrolled inflammatory and auto-immune responses that would otherwise harm self. T regulatory (Treg) cells are central to this process and are required to maintain self-tolerance by actively inhibiting self-reactive T cells by a variety of direct and indirect mechanisms. Numerous studies have sho

enmesh

Negative Regulators in Cancer Immunology and Immunotherapyk side” of tumor immunity is immune evasion. That is, by the time a patient suffers from a clinically-detectable tumor, the tumor has already successfully evaded cancer immunosurveillance and often has established effective mechanisms to actively suppress the immune system, particularly in the tumor

蛰伏

Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapyeptors (TCRs) or through the antigen-specific antibody-based chimeric antigen receptors (CARs). By either method, the advantage of the adoptive transfer of modified T cells over immunotherapies developed to date such as vaccines or cytokines alone is that T cells have the ability to directly traffic

合群

Diverticulitis

Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapyion status of histones affects levels of gene expression, and causes aberrant transcriptional repression in cancer cells. As a result, this is also implicated with unresponsiveness to immune-based therapies as well as conventional chemotherapies against cancer. To sensitize cancer cells to those the

暂时中止

Benign

https://doi.org/10.1007/978-1-60761-980-2Cancer; Immunotherapy; translational immunotherapy